title: Continuous versus intermittent prednimustine treatment of non-Hodgkin's lymphoma.
abstract: Seventy-eight patients with advanced non-Hodgkin's lymphomas were randomized for treatment with prednimustine (Sterecyt) in two different schedules: either receiving continuous treatment at a dosage of 60 mg daily, or intermittent two-week courses with 200 mg daily for five days. The aim of the study was to compare efficacy and side effects of the two different schedules. Forty patients received continuous, and 38 patients intermittent treatment. Objective response was achieved in 66% of 71 evaluable patients, equally distributed between the two treatment arms. The 10-year survival rate was 20% (SE = 6%; continuous treatment) and 11% (SE = 5%; intermittent treatment), respectively (logrank p = 0.26). Median time to response, duration of response and time to progression showed no significant difference between the treatment groups. Median time on treatment was longer for patients treated continuously, probably due to more easily performed dose adjustments in such patients. There was a significant decrease of the white blood cell counts in patients who received prednimustine continuously compared with those treated according to the intermittent schedule (p = 0.02). No significant differences were found regarding the thrombocyte levels. The response rate was closely related to haematological toxicity (p = 0.01). Our results suggest that prednimustine in non-Hodgkin's lymphomas has similar effectiveness both in daily treatment and in a two-weekly intermittent schedule. Continuously given treatment may be easier to govern and, thereby, allow for higher treatment intensity. With respect to toxicity, daily doses of approximately 30-40 mg in previously untreated patients may be recommended.
authors.affiliation: Department of Oncology, University Hospital, Linköping, Sweden.
authors.forename: T
authors.initials: T
authors.lastname: Hatschek
authors.forename: L
authors.initials: L
authors.lastname: Baldetorp
authors.forename: J
authors.initials: J
authors.lastname: Carstensen
authors.forename: L
authors.initials: L
authors.lastname: Håkansson
authors.forename: T
authors.initials: T
authors.lastname: Möller
authors.forename: B
authors.initials: B
authors.lastname: Nilsson
authors.forename: B
authors.initials: B
authors.lastname: Termander
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011238:Prednimustine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D011238:Prednimustine